Shanghai Junshi Biosciences Co., Ltd. Announces Poll Results of 2026 First Extraordinary General Meeting

Shanghai, 27 July 2026 – Shanghai Junshi Biosciences Co., Ltd. (Stock code: 1877), a leading biopharmaceutical company incorporated in the PRC, has announced the poll results from its 2026 first extraordinary general meeting (EGM), with significant implications for shareholders and the company’s future capital management.

Key Points from the EGM

• Approval of Share Repurchase Mandate: The main resolution tabled at the EGM was the proposal for a general mandate to repurchase the company’s H Shares. This special resolution was duly passed by an overwhelming majority, with 99.445% of votes in favor, 0.194% against, and 0.361% abstaining.
• Attendance and Voting: – Total issued shares: 1,026,689,871 (including 766,394,171 A Shares and 260,295,700 H Shares). – After excluding 815,871 treasury shares without voting rights, 1,025,874,000 shares were entitled to vote. – Shareholders or their proxies representing 270,778,987 shares attended the EGM, equating to a participation rate of 26.395%. – No shares required abstention, and there were no voting restrictions.
• Legal and Procedural Compliance: – The EGM was convened in compliance with all applicable laws, regulations, and the company’s Articles of Association. – Jia Yuan Law Offices, the company’s PRC legal adviser, confirmed the legality and validity of the EGM and voting process. – Tricor Investor Services Limited (H share registrar) and two shareholder representatives acted as scrutineers for the poll.
• Board and Leadership: – The EGM was chaired by Mr. Xiong Jun, Executive Director and Chairman of the Board. – All directors attended the meeting, demonstrating strong governance and oversight.

Important Information for Shareholders

• Repurchase Mandate Significance: The approval of the general mandate to repurchase H Shares empowers the Board to buy back company shares on the Hong Kong Stock Exchange, subject to applicable laws and regulations. Share repurchases are often viewed positively by investors as they can return value to shareholders, potentially support the share price, and signal confidence in the company’s prospects.
• Potential Share Price Impact: The ability to repurchase shares may help stabilize or enhance the market value of Junshi Biosciences’ H Shares, especially during periods of market volatility. This development could be seen as price-sensitive and is likely to be closely watched by investors and analysts.
• Transparency and Corporate Governance: The company has demonstrated transparency regarding the EGM proceedings, attendance, and voting outcomes, which may bolster investor confidence in management and governance practices.

Detailed Poll Results

Conclusion

The EGM outcome provides Shanghai Junshi Biosciences with greater flexibility in capital management through an approved share repurchase mandate. This move could positively influence the company’s share price and underlines management’s commitment to shareholder value. Investors should monitor future announcements for further details on any repurchase activities.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The author and publisher are not responsible for any losses arising from reliance on this information.

上海君實生物2026年第一次臨時股東大會表決結果詳情（廣東話版）

上海，2026年7月27日 – 國內領先生物製藥公司上海君實生物醫藥科技股份有限公司（股份代號：1877）公佈其2026年第一次臨時股東大會（EGM）表決結果，當中涉及股份回購授權，對公司股東及未來資本運作具有重要影響。

大會重點內容

• 股份回購授權通過： 大會表決的主要議案為授予公司董事會一般性授權，以回購公司H股股份。該特別決議最終高票通過，支持率高達99.445%，反對僅0.194%，棄權0.361%。
• 出席及投票詳情： – 公司總發行股份為1,026,689,871股（當中A股766,394,171股，H股260,295,700股）。
  – 扣除無投票權的庫藏股815,871股後，1,025,874,000股有權投票。
  – 出席會議的股東及授權代表合計代表270,778,987股，出席率為26.395%。
  – 沒有股份被要求回避或限制投票，程序公開透明。
• 法律及程序合規： – 會議召開及投票流程均符合法律法規及公司章程要求。 – 公司法律顧問嘉源律師事務所全程見證，並出具合法性意見書。 – H股過戶登記處卓佳證券登記有限公司及兩位股東代表作為監票人。
• 董事會及管理層： – 會議由執行董事會主席熊俊先生主持，所有董事均有出席，體現良好公司治理。

股東需注意的重要事項

• 股份回購授權意義： 此次通過的回購H股授權，賦予董事會於香港聯交所依法回購公司股份的權力。股份回購通常被視為利好消息，有助於提升股東回報，支持股價，並反映管理層對公司前景的信心。
• 對股價潛在影響： 回購授權有利於穩定公司H股市場價值，尤其在波動時段，屬於敏感信息，市場及投資者將密切關注公司後續動向。
• 公司治理及透明度： 君實生物在會議程序、出席情況及表決結果方面保持高度透明，有助於提升投資者對公司治理的信心。

表決結果詳情

總結

本次股東大會結果賦予公司更大資本操作靈活性。股份回購授權有望對公司H股股價帶來積極影響，反映管理層重視股東利益。投資者應持續關注公司後續公告，及時掌握回購動向。

免責聲明

本文僅作為信息分享，不構成任何投資建議或買賣邀約。投資者應自行調查並諮詢專業顧問，作者及發布方對因依賴本文信息導致的損失不承擔任何責任。

View JUNSHI BIO Historical chart here